Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 5

Coenzyme Q10 effects in neurodegenerative disease

Authors Meredith Spindler, M Flint Beal, Claire Henchcliffe

Published 9 November 2009 Volume 2009:5 Pages 597—610


Review by Single-blind

Peer reviewer comments 5

Meredith Spindler1, M Flint Beal1,2, Claire Henchcliffe1,2

1Department of Neurology, 2Department of Neuroscience, Weill Medical College of Cornell University, New York, NY, USA

Abstract: Coenzyme Q10 (CoQ10) is an essential cofactor in the mitochondrial respiratory chain, and as a dietary supplement it has recently gained attention for its potential role in the treatment of neurodegenerative disease. Evidence for mitochondrial dysfunction in neurodegenerative disorders derives from animal models, studies of mitochondria from patients, identification of genetic defects in patients with neurodegenerative disease, and measurements of markers of oxidative stress. Studies of in vitro models of neuronal toxicity and animal models of neurodegenerative disorders have demonstrated potential neuroprotective effects of CoQ10. With this data in mind, several clinical trials of CoQ10 have been performed in Parkinson’s disease and atypical Parkinson’s syndromes, Huntington’s disease, Alzheimer disease, Friedreich’s ataxia, and amyotrophic lateral sclerosis, with equivocal findings. CoQ10 is widely available in multiple formulations and is very well tolerated with minimal adverse effects, making it an attractive potential therapy. Phase III trials of high-dose CoQ10 in large sample sizes are needed to further ascertain the effects of CoQ10 in neurodegenerative diseases.

Keywords: coenzyme Q10, neurodegenerative disease, Parkinson’s disease, Huntington’s disease, mitochondrial dysfunction

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other articles by this author:

Rasagiline in treatment of Parkinson’s disease

Lakshmi Nayak, Claire Henchcliffe

Neuropsychiatric Disease and Treatment 2008, 4:11-20

Published Date: 8 February 2008

Readers of this article also read:

A new recombinant factor VIII: from genetics to clinical use

Kannicht C, Kohla G, Tiemeyer M, Walter O, Sandberg H

Drug Design, Development and Therapy 2015, 9:3817-3819

Published Date: 23 July 2015

A pilot randomized controlled trial using EEG-based brain–computer interface training for a Chinese-speaking group of healthy elderly

Lee TS, Quek SY, Goh SJA, Phillips R, Guan C, Cheung YB, Feng L, Wang CC, Chin ZY, Zhang H, Lee J, Ng TP, Krishnan KRR

Clinical Interventions in Aging 2015, 10:217-227

Published Date: 9 January 2015

Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients

Guerriero F, Sgarlata C, Marcassa C, Ricevuti G, Rollone M

Clinical Interventions in Aging 2015, 10:1-11

Published Date: 16 December 2014

Single event-related changes in cerebral oxygenated hemoglobin using word game in schizophrenia

Fujiki R, Morita K, Sato M, Yamashita Y, Kato Y, Ishii Y, Shoji Y, Uchimura N

Neuropsychiatric Disease and Treatment 2014, 10:2353-2360

Published Date: 11 December 2014

Association of Per3 length polymorphism with bipolar I disorder and schizophrenia

Karthikeyan R, Marimuthu G, Ramasubramanian C, Arunachal G, BaHammam AS, Spence DW, Cardinali DP, Brown GM, Pandi-Perumal SR

Neuropsychiatric Disease and Treatment 2014, 10:2325-2330

Published Date: 9 December 2014

Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke

Amiri-Nikpour MR, Nazarbaghi S, Ahmadi-Salmasi B, Mokari T, Tahamtan U, Rezaei Y

Neuropsychiatric Disease and Treatment 2014, 10:2299-2306

Published Date: 3 December 2014

Comparison of three screening tests for autism in preterm children with birth weights less than 1,500 grams

Dudova I, Markova D, Kasparova M, Zemankova J, Beranova S, Urbanek T, Hrdlicka M

Neuropsychiatric Disease and Treatment 2014, 10:2201-2208

Published Date: 17 November 2014


Channing J Paller, Emmanuel S Antonarakis

Drug Design, Development and Therapy 2011, 5:183-184

Published Date: 21 March 2011

Update on role of agalsidase alfa in management of Fabry disease

Uma Ramaswami

Drug Design, Development and Therapy 2011, 5:155-173

Published Date: 14 March 2011